Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
15 hedge funds and large institutions have $464K invested in Titan Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
209% more call options, than puts
Call options by funds: $349K | Put options by funds: $113K
0.09% more ownership
Funds ownership: 0.01% → 0.1% (+0.09%)
6% less funds holding
Funds holding: 16 → 15 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
60% less capital invested
Capital invested by funds: $1.15M → $464K (-$684K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$72.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$67K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$31.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$23.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$803K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$32K |
| 3 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$79 |
TTNP Hedge Fund Activity: Q4 2020 in Review
15 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2020, worth a combined $464K — down 60% from $1.15M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TTNP and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $72.5K. The largest seller was Sabby Management, exiting entirely with an estimated $803K sold.
- 15 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2020, down from 16 in Q3 2020.
- Funds reported $464K of Titan Pharmaceuticals stock for Q4 2020, down 60% quarter-over-quarter.
- 3 funds opened new Titan Pharmaceuticals positions in Q4 2020 and 4 closed out, a net change of -1 holder.
- The largest Titan Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $72.5K added.
- The largest Titan Pharmaceuticals seller in Q4 2020 was Sabby Management, an estimated $803K sold.
Based on aggregated 13F filings for Q4 2020.